NERVGEN PHARMA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.33 CAD | +7.87% |
|
+10.43% | -13.70% |
| Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
| Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 78.31 | 123.8 | 93.89 | 160.9 | 162.9 | - |
| Enterprise Value (EV) 1 | 78.31 | 123.8 | 93.89 | 160.9 | 162.9 | 162.9 |
| P/E ratio | -6.37 x | - | - | - | - | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | -14.1 x | -4.66 x | -13.9 x | -7.54 x | -5.22 x |
| EV / FCF | - | -15 x | -5.27 x | - | -10.9 x | -7.41 x |
| FCF Yield | - | -6.68% | -19% | - | -9.14% | -13.5% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 35,117 | 45,362 | 58,679 | 59,606 | 69,928 | - |
| Reference price 2 | 2.230 | 2.730 | 1.600 | 2.700 | 2.330 | 2.330 |
| Announcement Date | 4/8/21 | 2/28/22 | 3/30/23 | 4/17/24 | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | - | -8.753 | -20.13 | -11.59 | -21.6 | -31.2 |
| EBIT | - | -12.81 | -23.03 | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income | -11.19 | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| EPS | -0.3500 | - | - | - | - | - |
| Free Cash Flow 1 | - | -8.272 | -17.81 | - | -14.9 | -22 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/8/21 | 2/28/22 | 3/30/23 | 4/17/24 | - | - |
1CAD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -3.656 | -3.059 | -4.196 | -5.448 | -4.279 | -6.212 | -4.5 | -6.2 | -5.6 | -5.3 |
| EBIT | -3.667 | -4.147 | -5.004 | -6.313 | -4.924 | -6.784 | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | -3.599 | - | - | - | - | - | - | - | - | - |
| Net income | -3.599 | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS | -0.0900 | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/18/21 | 2/28/22 | 5/12/22 | 8/10/22 | 11/14/22 | 3/30/23 | - | - | - | - |
1CAD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -8.27 | -17.8 | - | -14.9 | -22 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 4/8/21 | 2/28/22 | 3/30/23 | 4/17/24 | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.33
CAD
Average target price
4.5
CAD
Spread / Average Target
+93.13%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.70% | 119M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- NGEN Stock
- Financials NervGen Pharma Corp.
